ABL503
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ABL503, covering 2025-02-06 to 2025-02-06. Get the full timeline:
Most recent: Clinical Trial Update: This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors [Phase 1]